ETON
Eton Pharmaceuticals, Inc.
ETON's fundamentals are strong: revenue about doubled and its operating margin went from −3.8% to 29%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ETON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
ETON's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ETON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $61.45 | — |
| Current | 41x | $61.45 | — |
| Cheap | 79x | $121 | +97% |
| Fair | 85x | $130 | +111% |
| Expensive | 149x | $227 | +269% |
Historical ranges are pointers, not guarantees.
ETON's PE is 41x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ETON Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
ETON has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ETON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.51 | +65% |
| Q3 2026 | $1.52 | +$1.77 |
| Q2 2026 | $0.39 | +$0.55 |
| Q1 2026 | -$0.06 | +$0.12 |
| Q4 2025 | -$0.17 | -$0.02 |
| Q3 2025 | -$0.25 | -$0.03 |
| Q2 2025 | -$0.16 | +$0.10 |
| Q1 2025 | -$0.18 | -550% |
| Q4 2022 | -$0.35 | -$0.27 |
ETON has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ETON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $57.9M | +158% |
| Q2 2026 | $37.6M | +99% |
| Q1 2026 | $24.3M | +40% |
| Q4 2025 | $21.3M | +83% |
| Q3 2025 | $22.5M | +118% |
| Q2 2025 | $18.9M | +109% |
| Q1 2025 | $17.3M | +117% |
| Q4 2024 | $11.6M | +59% |
ETON has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | +46 points |
| Q2 2026 | 34% | +42 points |
| Q1 2026 | 10% | +13 points |
| Q4 2025 | 12% | +6.2 points |
| Q3 2025 | -6.1% | -11 points |
| Q2 2025 | -7.8% | +25 points |
| Q1 2025 | -2.7% | +7.3 points |
| Q4 2024 | 5.4% | +33 points |
ETON has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ETON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.2M | +200% |
| Q2 2026 | $7.3M | -8.8% |
| Q1 2026 | $7.3M | +251% |
| Q4 2025 | -$11.6M | -$10.8M |
| Q3 2025 | $11.7M | +298% |
| Q2 2025 | $8M | +534% |
| Q1 2025 | $2.1M | +$4.6M |
| Q4 2024 | -$777K | -301% |
ETON generated $38M in free cash flow over the past year, up 82% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ETON on cash flow, with more consistent year-over-year improvement.
ETON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +477K shares |
| 1 year | +24% | +6.4M shares |
| 3 years | +32% | +8.1M shares |
| 5 years | +58% | +12.2M shares |
ETON has 33M diluted shares, up 24% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ETON on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ETON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | -9.6x | Net Cash |
| Q2 2025 | 2.6x | Moderate |
| Q1 2024 | -7.9x | Net Cash |
| Q3 2023 | -7.1x | Net Cash |
ETON has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ETON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.9 | Neutral |
| Stochastic | 58.6 | Neutral |
ETON's weekly RSI is 70 (neutral) and its Stochastic is 59 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ETON PE vs Healthcare Sector
| Metric | ETON | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 57% above |
| PE % | 4 | 29 | 25 pts below |
ETON is trading at 41x earnings, a 57% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ETON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $54.8 | 12% above |
| 20 week MA | $52.1 | 18% above |
| 50 week MA | $34.3 | 79% above |
| 100 week MA | $25.2 | 144% above |
| 200 week MA | $14.9 | 313% above |
ETON has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ETON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.02 | $8.78 | +25% |
| 2021 | $8.78 | $4.26 | -51% |
| 2022 | $4.26 | $3.05 | -28% |
| 2023 | $3.05 | $4.38 | +44% |
| 2024 | $4.38 | $13.1 | +198% |
| 2025 | $13.1 | $16.8 | +29% |
| 2026 YTD | $16.8 | $61.5 | +265% |
ETON has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.